We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effects of XueZhiTong capsules on chronic kidney disease patients with dyslipidemia.
- Authors
Ya Feng; Weichun Liang; Wei Liang; Xiang Xiao; Yalan Zhang
- Abstract
Purpose: To determine the clinical effectiveness of Xuezhitong capsule in chronic kidney disease (CKD) patients with dyslipidemia, and its influence on inflammation and oxidative stress. Methods: Ninety CKD patients with dyslipidemia who were admitted to the Department of Nephrology of our hospital from January 2018 to January 2020 were randomly assigned to group A (treated with Xuezhitong capsules), group B (treated with combination of Xuezhitong capsules and atorvastatin), and group C (treated with atorvastatin), with 30 cases in each group. Renal function, lipid indicators, inflammatory indicators, and degree of oxidative stress were compared among the three groups of patients after 3 consecutive months of treatment. Results: At 3 months after treatment, estimated glomerular filtration rate (eGFR) and urinary albumin creatinine ratio (UACR) were markedly decreased in all three groups (p < 0.05). After treatment, the levels of TC, TGs, and LDL-C were decreased markedly and time-dependently in the three groups, with the lowest levels in group B, while HDL-C level was elevated with treatment time, with the highest level in group B (p < 0.05). After treatment, the 3 groups exhibited significant decreases in levels of hypersensitive C-reactive protein (hs-CRP), homocysteine (Hcy), and malondialdehyde (MDA), with the lowest levels in group B (p < 0.05). Adiponectin level was significantly increased in each of the 3 groups (p < 0.05). Conclusion: Xuezhitong capsules exerted lipid-lowering effect and mitigated inflammation and oxidative stress in CKD patients with dyslipidemia, without any adverse effects. This finding provides a new treatment option for elderly CKD patients with dyslipidemia.
- Subjects
CHRONIC kidney failure; CHRONICALLY ill; LIPIDS; DYSLIPIDEMIA; GLOMERULAR filtration rate; OLDER patients
- Publication
Tropical Journal of Pharmaceutical Research, 2022, Vol 21, Issue 1, p177
- ISSN
1596-5996
- Publication type
Article
- DOI
10.4314/tjpr.v21i1.26